- Home
- Publications
- Publication Search
- Publication Details
Title
Novel Pharmacotherapy Options for NASH
Authors
Keywords
Nonalcoholic steatohepatitis, Elafibranor, Obeticholic acid, Cenicriviroc, Aramchol, Liraglutide
Journal
DIGESTIVE DISEASES AND SCIENCES
Volume 61, Issue 5, Pages 1398-1405
Publisher
Springer Nature
Online
2016-03-22
DOI
10.1007/s10620-016-4128-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design
- (2016) Scott Friedman et al. Contemporary Clinical Trials
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
- (2016) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
- (2015) Gideon M. Hirschfield et al. GASTROENTEROLOGY
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- (2015) Paul Angulo et al. GASTROENTEROLOGY
- Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop
- (2015) Arun J. Sanyal et al. HEPATOLOGY
- Current efforts and trends in the treatment of NASH
- (2015) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
- (2015) Michal Pawlak et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease
- (2014) Rifaat Safadi et al. Clinical Gastroenterology and Hepatology
- Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease
- (2014) Pierre Bedossa et al. HEPATOLOGY
- Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation
- (2014) William Peverill et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Peroxisome proliferator-activated receptor δ
- (2013) Lazar A. Bojic et al. CURRENT OPINION IN LIPIDOLOGY
- Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
- (2013) B. Cariou et al. DIABETES CARE
- An overview of patented small molecule stearoyl coenzyme-A desaturase inhibitors (2009 – 2013)
- (2013) David A Powell EXPERT OPINION ON THERAPEUTIC PATENTS
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
- (2013) Len Verbeke et al. HEPATOLOGY
- Bile acid receptors as targets for drug development
- (2013) Frank G. Schaap et al. Nature Reviews Gastroenterology & Hepatology
- Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
- (2013) Peter G. Traber et al. PLoS One
- Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease
- (2013) Peter G. Traber et al. PLoS One
- The Role of Gastrointestinal Hormones in Hepatic Lipid Metabolism
- (2013) Jamie Mells et al. SEMINARS IN LIVER DISEASE
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2
- (2012) Kouichi Miura et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
- (2012) Luciano Adorini et al. DRUG DISCOVERY TODAY
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- (2012) Naga Chalasani et al. HEPATOLOGY
- Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study
- (2012) Thierry Poynard et al. JOURNAL OF HEPATOLOGY
- Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
- (2011) G. Vernon et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet
- (2011) Jamie E. Mells et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
- (2011) A. J. Garber DIABETES CARE
- Effects of the New Dual PPAR / Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
- (2011) B. Cariou et al. DIABETES CARE
- Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury
- (2011) Christer Baeck et al. GUT
- Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality
- (2011) Zobair M. Younossi et al. HEPATOLOGY
- Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis
- (2011) Gianluca Svegliati-Baroni et al. LIVER INTERNATIONAL
- Fatty Acid Bile Acid Conjugate Inhibits Hepatic Stearoyl Coenzyme A Desaturase and Is Non-atherogenic
- (2010) Alicia Leikin-Frenkel et al. ARCHIVES OF MEDICAL RESEARCH
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
- (2010) Nitika Arora Gupta et al. HEPATOLOGY
- Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites
- (2010) Brent A. Neuschwander-Tetri HEPATOLOGY
- Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice
- (2010) Marie-Luise Berres et al. JOURNAL OF CLINICAL INVESTIGATION
- A position statement on NAFLD/NASH based on the EASL 2009 special conference
- (2010) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment
- (2010) Vivian Barry-Hamilton et al. NATURE MEDICINE
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
- (2009) Kittichai Promrat et al. HEPATOLOGY
- Decreased survival of subjects with elevated liver function tests during a 28-year follow-up
- (2009) Cecilia Söderberg et al. HEPATOLOGY
- The regulation of inflammation by galectin-3
- (2009) Neil C. Henderson et al. IMMUNOLOGICAL REVIEWS
- Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
- (2009) Songwen Zhang et al. JOURNAL OF HEPATOLOGY
- Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
- (2009) Curtis K. Argo et al. JOURNAL OF HEPATOLOGY
- Galectins: structure, function and therapeutic potential
- (2008) Ri-Yao Yang et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Peroxisome proliferator-activated receptor-δ induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice
- (2008) Xiaomei Qin et al. HEPATOLOGY
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
- (2008) Yan-Dong Wang et al. HEPATOLOGY
- Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
- (2008) Adrian M. Di Bisceglie et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now